11 results
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
25 Apr 24
Current report (foreign)
4:06pm
on assets (excluding interest expenses) – – (67) (67) Actuarial gains/(losses) related to changes in demographic assumptions – (13) – (13) Actuarial … in demographic assumptions – 54 – 54 Actuarial gains/(losses) related to changes in financial assumptions 2,846 – – 2,846 Other actuarial gains
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
28 Apr 23
Current report (foreign)
4:05pm
/received 2,140 – (2,140) – Return on assets (excluding interest expenses) – – 34 34 Actuarial gains/(losses) related to changes in demographic … ) related to changes in demographic assumptions 349 77 – 426 Actuarial gains/(losses) related to changes in financial assumptions 1,120 – – 1,120 Other
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
29 Apr 22
Current report (foreign)
4:02pm
. The treatment effects for the primary endpoint of UPCR at 9 months were consistent across key subgroups, including key demographic and baseline disease … (excluding interest expenses) – – 64 64 Actuarial gains/(losses) related to changes in demographic assumptions 349 77 – 426 Actuarial gains/(losses) related
20-F/A
EX-15.1
uu83r0qf45cun
14 Jan 22
Annual report (foreign) (amended)
5:13pm
6-K
EX-99.1
70ei8
16 Dec 21
Current report (foreign)
4:01pm
424B5
k4uyuh
12 Aug 21
Prospectus supplement for primary offering
5:10pm
F-3ASR
awptr e4f
12 Jul 21
Automatic shelf registration (foreign)
5:10pm
6-K
EX-99.1
iqhwypju k035zrwb
27 Apr 21
Current report (foreign)
12:00am
- Prev
- 1
- Next